A Randomized Phase II Trial of Cytotoxic Chemotherapy With or Without Epigenetic Priming in Patients With Advanced Non-Small Cell Lung Cancer

Trial Profile

A Randomized Phase II Trial of Cytotoxic Chemotherapy With or Without Epigenetic Priming in Patients With Advanced Non-Small Cell Lung Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Entinostat (Primary) ; Docetaxel; Gemcitabine; Irinotecan; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Apr 2017 Status changed from active, no longer recruiting to discontinued.
    • 03 May 2016 Status changed from recruiting to active, no longer recruiting.
    • 13 Jul 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Jan 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top